Pulmozyme sales in Western Europe alone were about CHF 100 million in 2012 (Roche reports CHF 74 million as at September 2012 and I have projected as at Dec 2012). This is about A$100 million per annum.
PXS have said that they have 10% of the adult market in Germany (about 3500 adult patients) and this is growing.
Adult patient reimbursement for Bronchitol is now possible in the UK (4500 adult patients)
Germany and the UK are the largest CF markets in Western Europe.
PXS is on the March agenda of the PBAC seeking to simply access to Bronchitol for Australian patients
The US setback is disapointing but we know that the product works and that growth is occuring.
response letter, page-31
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
